Clinical Trial Update: Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating infusion of donor lymphocytes depleted of CD25+ regulatory T-cells in patients with relapsed hematologic malignancies; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• Donor Lymphocyte Infusion (CD25+ Regulatory T-cell Depleted) (donor lymphocytes depleted of CD25+ regulatory T-cells)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Hematologic Malignancies | Phase 1 | Status: COMPLETED